Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management

and anti-ganglioside antibodies, as well as the revised role of electrodiagnosis, as an exclusively diagnostic tool rather than allowing definite and meaningful subtype classification. Established prognostication models such as Erasmus GBS Outcome Score and Erasmus GBS Respiratory Insufficiency Score as well as emerging fluid biomarker candidates spanning biochemical, immunological, nerve-structural markers are reviewed. Advances in neuroimaging that aid in diagnosis and subtyping of GBS are also discussed. Finally, we highlight the evidence reaffirming intravenous immunoglobulin or plasma exchange as current standard-of-care and critically evaluate ongoing and recently completed trials including complement inhibitors.